

# Artificial intelligence-assisted meta-analysis of the frequency of ACE I/D polymorphisms in centenarians and other long-lived individuals

Lingxuan Li and Shin Murakami\*

Department of Basic Sciences, College of Osteopathic Medicine, Touro University California, Vallejo, CA 94592.

\*, Corresponding author, Shin Murakami, PHD, FGSA

## Abstract

Current research on the angiotensin-converting-enzyme (ACE) gene has yielded controversial results on whether different ACE polymorphisms are linked with human longevity. ACE polymorphisms are a risk factor for Alzheimer's disease and age-onset diseases that may contribute to the mortality of older people. Our goal is to consolidate existing studies with assistance from artificial intelligence and machine-learning-assisted software to come to a more precise understanding of the role of the ACE gene in human longevity. The I (insertion) and D (deletion) polymorphisms in the intron are correlated with the levels of circulating ACE; homozygous D (DD) is high and homozygous I (II) is low. Here, we performed a detailed meta-analysis of the I and D polymorphisms using centenarians (100+ years old), long-lived subjects (85+ years old), and control groups. ACE genotype distribution was analyzed across a total of 2,054 centenarians and 12,074 controls, as well as 1,367 long-lived subjects between the ages of 85-99, using the inverse variance and random effects methods. The ACE DD genotype was found to be favored in centenarians (OR: 1.41 [95% CI: 1.19-1.67],  $P < 0.0001$ ) with a heterogeneity of 32%, and the II genotype slightly favored the control groups (OR: 0.81 [95% CI: 0.66-0.98],  $P = 0.03$ ) with a heterogeneity of 28%, corroborating results from previous meta-analyses. Novel to our meta-analysis, the ID genotype was found to be favored in control groups (OR: 0.86 [95% CI: 0.76-0.97],  $P = 0.01$ ) with a heterogeneity of 0%. The long-lived group showed a similar positive association between the DD genotype and longevity (OR: 1.34 [95% CI: 1.21-1.48],  $P < 0.0001$ ) and a negative association between the II genotype and longevity (OR: 0.79 [95% CI: 0.70-0.88],  $P < 0.0001$ ). The long-lived ID genotype did not show significant findings (OR: 0.93 [95% CI: 0.84-1.02],  $P = 0.79$ ). In conclusion, the results suggest a significant positive association of the DD genotype with human longevity. However, despite the previous study, the results do not confirm a positive association of the ID genotype with human longevity. We suggest a few paradoxical observations: (1) inhibition of ACE can increase longevity in model systems from nematodes to mammals, seemingly opposite to the finding in humans; (2) exceptional longevity associated with homozygous DD is also associated age-related diseases with higher mortality risks in homozygous DD. We discuss ACE, longevity, and age-related diseases.

## Introduction

45 Human life expectancy has increased in the past millennia since the studies of longevity in  
46 ancient Greek and Roman populations (Montagu, 1994; Batrinos, 2008; Roser et al., 2013). The  
47 study of aging, including the biology of aging and populations of older people, has suggested  
48 that longevity is influenced by a combination of genetic, lifestyle, and environmental factors  
49 (reviewed in Weinert et al., 2003). The search for genetic causes of longevity has implicated  
50 several possible candidate genes, including SIRT1, APOE, FOXO3A, ACE, ATM, NOS1, NOS2,  
51 KLOTHO and IL6 (reviewed in Revelas et al., 2018; Costa et al., 2019). Of them, ACE encodes an  
52 angiotensin-converting enzyme, which has two functions with opposing effects on health (Duc  
53 et al., 2020; Duc et al., 2021). Firstly, ACE is an essential enzyme for hemodynamic control via  
54 the renin-angiotensin-aldosterone system and the kinin-kallikrein system. ACE converts the  
55 inactive angiotensin I to the active angiotensin II, a potent vasoconstrictor, and inactivates  
56 bradykinin, a potent vasodilator. ACE inhibitors are one of the first-line treatments for  
57 hypertension and congestive heart failure. In this function, ACE inhibition is beneficial to health  
58 through controlling hypertension. Secondly, ACE is an amyloid-degrading enzyme that can  
59 reduce the proteo-toxicity of amyloid. Importantly, ACE, when altered, is a risk factor gene in  
60 Alzheimer's disease (Vahdati Nia et al., 2017; Murakami and Lacayo, 2022). ACE alterations are  
61 associated with Alzheimer's disease (discussed in Duc et al., 2021). In this function, ACE  
62 inhibition may be deleterious to the health through amyloid toxicity. Thus, the effect of ACE on  
63 longevity may differ depending on the health conditions of advanced aging (Duc et al., 2021).  
64 Thus, we reason that long-lived groups should be included in this study.

65  
66 The ACE gene is located on chromosome 17q23. The ACE I/D polymorphisms were first  
67 identified in 1990, which are characterized by the presence (insertion, I) or absence (deletion,  
68 D) of a 287-bp (base pair) Alu repeat sequence in intron 16 (Rigat et al., 1990). The I/D  
69 polymorphisms correlated with the serum levels of circulating ACE; the D-allele is higher and  
70 the I-allele is lower (Tiret et al., 1992). The DD individuals have approximately twice the plasma  
71 ACE levels as the II individuals do (Rigat et al., 1990; Tomita et al., 1996). Other meta-analyses  
72 have also shown a positive association between the D-allele and increased risk of essential  
73 hypertension (Li et al., 2011), ischemic stroke (Zhang et al., 2012), coronary artery disease  
74 (Zintzaras et al., 2008), left ventricular hypertrophy (Li et al., 2012) and pneumonia (Nie et al.,  
75 2014). In addition, the D-allele has been linked with higher mortality rates from COVID-19  
76 (Yamamoto et al., 2020).

77  
78 Paradoxically, the ACE D allele is associated with the risk of cardiovascular disease,  
79 hypertension, Alzheimer's disease, and other common causes of death in older people, while a  
80 previous study noted an increased frequency of the DD genotype among a group of  
81 centenarians from France (Schachter et al., 1994). Since then, centenarian studies have been  
82 performed across different cohorts, resulting in conflicting results. A more recent study  
83 suggests that the DD genotype and the D allele are enriched in centenarians (Garatachea et al.,  
84 2013), while another study suggests that no significant difference among the I and D alleles  
85 (Choi et al., 2003; Oscanoa, et al., 2020). In this meta-analysis, we further consolidated these  
86 findings to more precisely determine whether or not the D polymorphism is enriched in  
87 centenarians and long-lived individuals.

88

89

## 90 **Methods**

91

### 92 *Nomenclature, PRISMA and Database search*

93

94 Due to nomenclature inconsistency among studies, we used I (Insertion) and D (deletion) alleles  
95 as follows: The genotypes were referred to as homozygous insertion (II), heterozygous  
96 insertion/deletion (ID), and homozygous deletion (DD). The I and D polymorphisms were  
97 referred to as I/D. We followed the Preferred Reporting Items for Systematic Reviews and  
98 Meta-Analyses (PRISMA) (Moher et al., 2009) and performed a meta-analysis as described  
99 (Antos et al., 2021) with updates described in PRISMA 2020 (Page et al., 2021). We performed a  
100 literature search to collect all publications on ACE I/D polymorphisms in centenarians published  
101 before May 25, 2022. A total of 80 studies were obtained from the Human Genomic Aging  
102 Resource's Longevity Map database, Scopus, PubMed, and Google Scholar using the keywords  
103 "ACE" OR "angiotensin-converting enzyme" AND "longevity" OR "centenarian" OR  
104 "nonagenarian" (subjects 90+ years). Studies of all languages were included. The titles and  
105 abstracts of each article were imported to Colandr (Cheng et al., 2018) which uses AI and  
106 machine-learning algorithms to determine an article's relevance based on text-based evidence.  
107 Of the 80 studies initially identified, 37 were excluded as duplicates. The remaining 43 articles  
108 were then screened in Colandr according to specified inclusion criteria.

109

### 110 *Inclusion criteria*

111

112 Studies were included if they met all of the following conditions: (1) evaluation of the ACE I/D  
113 polymorphisms and longevity; (2) case-control study design; (3) study provides sample size,  
114 genotype data, odds ratio (OR) and 95% confidence interval (CI), or the data necessary to  
115 calculate the results. The exclusion criteria of the studies were as follows: (1) not relevant to  
116 ACE I/D polymorphisms or longevity; (2) review or meta-analysis; (3) minimum long-lived  
117 population age < 85 years or unspecified; (4) no control group or maximum control group age >  
118 85 years. Data was then separated into centenarian-only and long-lived (85+ years old)  
119 sections. Studies were included in the centenarian-only section if the mean population age was  
120 > 100. In total, we obtained 13 papers that met all our inclusion criteria for centenarians and 19  
121 papers for the long-lived group.

122

### 123 *Data extraction*

124


125 Data were extracted independently by the author and an assistant, and any discrepancies were  
126 settled by consensus. The data extracted included the author's name, year of publication,  
127 ethnicity of the study population, sample size, and genotype numbers in long-lived and control  
128 groups. Allele frequencies were calculated if not directly reported. If the study had multiple  
129 control groups of varying age ranges, the control group was defined as all individuals ≤ 85 years  
130 of age, and data was extracted accordingly.

131

### 132 *Data synthesis and assessment of the risk of bias*

133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143

To determine the association between ACE genotype and longevity, the odds ratio (OR) with the corresponding 95% confidence interval (CI) was calculated for each genotype (DD, ID, and II). All statistical analyses were performed using The Cochrane Collaboration's Review Manager (RevMan) Version 5.4 using the random effects statistical model and inverse variance methods. The risk of bias in the studies was performed as described by Antos et al., 2021. The result was visualized with Risk-of-bias VISualization (robvis) ROBINS-1 (Sterne et al., 2016; McGuinness et al., 2021). Bias due to deviations from intended interventions did not apply to this meta-analysis, as participants were categorized by age and could not be blinded in which group they were assigned.



144  
145  
146  
147

**Figure 1.** Flow diagram of the literature search. A total of 80 studies were gathered from SCOPUS (n = 39), PubMed (n = 26) and Google Scholar (n = 15). Excluding 33 duplicates and 4

148 studies with irrelevant titles, 43 remaining studies were selected for abstract examination.  
149 Following the abstract screening, 2 studies were excluded for having the wrong study design  
150 and 13 studies were excluded for defining their minimum long-lived population age to be < 85  
151 years of age. The full-text review was performed on the remaining 28 studies, and 9 of those  
152 were excluded as the data was not usable, meaning that the study collected and presented data  
153 in a form other than the frequency of individuals genotypes and that the frequency of  
154 genotypes was not able to be calculated from the data available.

155

156

157

## 158 **Results**

### 159 *I. Centenarian results:*

160

161 Our literature search is summarized in Figure 1. The extracted data of centenarians from the  
162 identified studies are summarized in Table 1. The meta-analysis included 13 studies (Bladbjerg  
163 et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da Silva et al., 2018; Faure-Delanef  
164 et al., 1998; Fiuza-Luces et al., 2011; Nacmias et al., 2007; Panza et al., 2002, 2003; Schachter et  
165 al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Zhang et al., 2010), involving a total of 2,054  
166 centenarians and 10,986 controls. Ethnicities of the studied populations were Caucasian (n =  
167 10), Korean (n = 1), Uyghur (n = 1) and Han Chinese (n = 1). This meta-analysis investigated  
168 what age groups could be analyzed. We found three age groups that consistently showed up  
169 among the previous studies, resulting in centenarians (100+ years old), long-lived groups (85+  
170 years old), and control groups. The range of the control groups was diverse among previous  
171 studies. We set the ages of control groups as 18-85 year old which was judged to be inclusive to  
172 most of the studies.

173

174 The major differences from the previous meta-analysis were as follows. Firstly, we used  
175 different age groups for a more precise understanding of the effect of ACE on longevity. The  
176 previous meta-analysis compared the frequencies of various combinations of I and D (i.e., DD  
177 vs. II; DD vs. ID; ID vs. II; DD + ID vs. II; and DD vs. ID + II) (Garatachea et al., 2013), which lacked  
178 comparisons among different age groups. Secondly, we excluded a study (Paolisso et al., 2001),  
179 which was used in the previous meta-analysis (Garatachea et al., 2013) for the following reason:  
180 The excluded study used 62-88 years old, which overlapped with the age range for the long-  
181 lived group (85+ years old) commonly used in previous studies (see II. Long-Lived Results).  
182 Finally, we incorporated AI-assisted software to reduce the burden of the meta-analysis studies.

183

184

185 **Table 1.** Characteristics of studies on ACE I/D polymorphisms in centenarians. A total of 13  
186 studies were included that looked at the frequency of different ACE I/D polymorphisms in  
187 centenarians.

188

	Year	Centenarian		Control		Ethnicity
		# of subjects	Age (years) Mean $\pm$ SD	# of subjects	Age (years) Range	
Schachter et al.	1994	310	100.71 $\pm$ 0.13	164	20-70	Caucasian
Faure-Delanef et al.	1998	150	100.6	74	20-70	Caucasian
Bladbjerg et al.	1999	185	>100	199	20-64	Caucasian
Blanche et al.	2001	560	103.1	560	18-70	Caucasian
Panza et al.	2002	63	100.3 $\pm$ 1.9	204	19-80	Caucasian
Choi et al.	2003	102	102.4 $\pm$ 2.6	7229	20-85	Korean
Panza et al.	2003	82	100 $\pm$ 2	252	19-70	Caucasian
Wufuer et al.	2004	42	103.0 $\pm$ 3.0	53	65-70	Uyghur
Seripa et al.	2006	64	100.28 $\pm$ 1.86	1191	22-59	Caucasian
Nacmias et al.	2007	111	102.4 $\pm$ 2.6	192	84 $\pm$ 18.2	Caucasian
Zhang et al.	2010	27	>100	79	60-70	Han Chinese
Fiuza-Luces et al.	2011	65	101.7 $\pm$ 1.8	283	21.2 $\pm$ 2.0	Caucasian
Pereira da Silva et al.	2018	253	100.26 $\pm$ 1.98	268	67.51 $\pm$ 3.25	Caucasian

189

190


191 As shown in Figure 2, the association between the DD genotype and exceptional longevity was  
192 analyzed in 13 studies (Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da  
193 Silva et al., 2018; Faure-Delanef et al., 1998; Fiuza-Luces et al., 2011; Nacmias et al., 2007;  
194 Panza et al., 2002, 2003; Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Zhang  
195 et al., 2010). The DD genotype was more frequent among centenarians than in controls, with an  
196 OR of 1.41 (95% CI: 1.19-1.67,  $P < 0.0001$ ) with mild heterogeneity (32%), indicating a significant  
197 positive association between the DD genotype and longevity.

198

199




It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



200  
201 **Figure 2:** Comparison of DD genotype frequency in centenarians and control groups. The ages  
202 of centenarians and control groups are as described in Table 1.

203  
204  
205 As shown in Figure 3, the association between the ID genotype and exceptional longevity was  
206 analyzed in 13 studies (Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da  
207 Silva et al., 2018; Faure-Delaneuf et al., 1998; Fiuza-Luces et al., 2011; Nacmias et al., 2007;  
208 Panza et al., 2002, 2003; Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Zhang  
209 et al., 2010). The ID genotype was found to have an OR of 0.86 (95% CI: 0.76-0.97, P = 0.01)  
210 with no evidence of heterogeneity (0%), indicating a significant negative association between  
211 the ID genotype and longevity.




214  
215 **Figure 3:** Comparison of ID genotype frequency in centenarians and control groups. The ages  
216 of centenarians and control groups are described in Table 1.

217  
218  
219 As shown in Figure 4, the association between the II genotype and exceptional longevity was  
220 analyzed in 13 studies (Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da  
221 Silva et al., 2018; Faure-Delaneuf et al., 1998; Fiuza-Luces et al., 2011; Nacmias et al., 2007;

222 Panza et al., 2002, 2003; Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Zhang  
 223 et al., 2010). The II genotype was found to have an OR of 0.81 (95% CI: 0.66-0.98, P = 0.03) with  
 224 mild heterogeneity (28%), indicating a significant negative association between the II genotype  
 225 and longevity.

226  
 227



228  
 229 **Figure 4:** Comparison of II genotype frequency in centenarians and control groups. The ages of  
 230 centenarians and control groups are as described in Table 1.

231  
 232  
 233 *II. Long-Lived Results:*

234  
 235 Table 2 summarizes the data of long-lived groups. The meta-analysis included 19 studies, with  
 236 13 centenarian-only studies, and 5 studies that included both nonagenarians and centenarians  
 237 (Arkhipova et al., 2014; Kolovou et al., 2014; Lo Sasso et al., 2012; Oscanoa et al., 2020; Yang et  
 238 al., 2009), and 1 study with individuals 85 years and older (Heijmans et al., 1999), involving a  
 239 total of 3,421 long-lived individuals (85+ years old) and 11,959 controls. Ethnicities of the  
 240 studied populations were Caucasian (n = 13), Korean (n = 1), Uyghur (n = 1), Han Chinese (n =  
 241 2), Russian/Yakut (n = 1), and Peruvian (n = 1).


242  
 243 The association between the DD genotype and exceptional longevity was analyzed in 18 studies  
 244 (Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da Silva et al., 2018;  
 245 Faure-Delanef et al., 1998; Fiuza-Luces et al., 2011; Kolovou et al., 2014; Lo Sasso et al., 2012;  
 246 Nacmias et al., 2007; Oscanoa et al., 2020; Panza et al., 2002, 2003; Schachter et al., 1994;  
 247 Seripa et al., 2006; Wufuer et al., 2004; Yang et al., 2009; Zhang et al., 2010). The DD genotype  
 248 was found to have an OR of 1.32 (95% CI: 1.19-1.47, P < 0.00001) with mild heterogeneity  
 249 (30%), indicating a significant positive association between the DD genotype and longevity.

250  
 251  
 252 **Table 2.** Characteristics of studies on ACE I/D polymorphisms in long-lived individuals (85+ years  
 253 old).



	Year	Long-lived		Control		Ethnicity
		# of subjects	Age (years) Mean $\pm$ SD	# of subjects	Age (years) Range/Mean $\pm$ SD	
Schachter et al.	1994	310	100.71 $\pm$ 0.13	164	20-70	Caucasian
Faure-Delanef et al.	1998	150	100.6	74	20-70	Caucasian
Bladbjerg et al.	1999	185	>100	199	20-64	Caucasian
Heijmans et al.	1999	353	85-100	250	18-40	Caucasian
Blanche et al.	2001	560	103.1	560	18-70	Caucasian
Panza et al.	2002	63	100.3 $\pm$ 1.9	204	19-80	Caucasian
Choi et al.	2003	102	102.4 $\pm$ 2.6	7229	20-85	Korean
Panza et al.	2003	82	100 $\pm$ 2	252	19-70	Caucasian
Wufuer et al.	2004	42	103.0 $\pm$ 3.0	53	65-70	Uyghur
Seripa et al.	2006	64	100.28 $\pm$ 1.86	1191	22-59	Caucasian
Nacmias et al.	2007	111	102.4 $\pm$ 2.6	192	84 $\pm$ 18.2	Caucasian
Yang et al.	2009	399	>90	302	<60	Han Chinese
Zhang et al.	2010	27	>100	79	60-70	Han Chinese
Fiuza-Luces et al.	2011	65	101.7 $\pm$ 1.8	283	21.2 $\pm$ 2.0	Caucasian
Lo Sasso et al.	2012	361	97	394	39	Caucasian
Arkhipova et al.	2014	44	>90	115	60-74	Russian, Yakut
Kolovou et al.	2014	198	$\geq$ 90	105	18-79	Caucasian
Pereira da Silva et al.	2018	253	100.26 $\pm$ 1.98	268	67.51 $\pm$ 3.25	Caucasian
Oscanoa et al.	2020	6	>85	14	<65	Peruvian

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




256  
257 **Figure 5.** Comparison of DD genotype frequency in long-lived and control groups. The ages of  
258 long-lived and control groups are described in Table 1.

259  
260  
261 As shown in Figure 6, the association between the ID genotype and exceptional longevity was  
262 analyzed in 18 studies (Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da  
263 Silva et al., 2018; Faure-Delaneuf et al., 1998; Fiuza-Luces et al., 2011; Kolovou et al., 2014; Lo  
264 Sasso et al., 2012; Nacmias et al., 2007; Oscanoa et al., 2020; Panza et al., 2002, 2003;  
265 Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Yang et al., 2009; Zhang et al.,  
266 2010).

267  
268 The ID genotype was found to have an OR of 0.92 (95% CI: 0.84-1.02, P = 0.11) with no evidence  
269 of heterogeneity (0%). There was no significant difference in the frequency of the ID genotype  
270 between the long-lived (85+ years old) and control groups.

271  
272



273

274 **Figure 6.** Comparison of ID genotype frequency in long-lived and control groups. The ages of  
 275 long-lived and control groups are described in Table 1.

276


277

278 As shown in Figure 7, the association between the II genotype and exceptional longevity was  
 279 analyzed in 19 studies (Arkhipova et al., 2014; Bladbjerg et al., 1999; Blanche et al., 2001; Choi  
 280 et al., 2003; Pereira da Silva et al., 2018; Faure-Delaneuf et al., 1998; Fiuza-Luces et al., 2011;  
 281 Kolovou et al., 2014; Lo Sasso et al., 2012; Nacmias et al., 2007; Oscanoa et al., 2020; Panza et  
 282 al., 2002, 2003; Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Yang et al., 2009;  
 283 Zhang et al., 2010). Arkhipova et al., 2014 only provided raw frequency data for the II genotype  
 284 and thus was not included in the DD or ID analyses. The II genotype was found to have an OR of  
 285 0.80 (95% CI: 0.71-0.90, P = 0.002) with mild heterogeneity (30%), indicating a significant  
 286 negative association between the II genotype and longevity. The risk of bias of the studies was  
 287 assessed using ROBINS-1 (Method). As shown in Figure 8, the result suggests an overall low risk  
 288 of bias.

289

290

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .



291

292

293

294

295

**Figure 7.** Comparison of II genotype frequency in long-lived and control groups. The ages of long-lived and control groups are described in Table 1.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


Study	Risk of bias domains							Overall
	D1	D2	D3	D4	D5	D6	D7	
Schachter et al., 1994	+	+	+	?	+	+	+	+
Faure-Delaneuf et al., 1998	+	+	+	?	+	+	+	+
Bladbjerg et al., 1999	+	+	+	?	+	+	+	+
Heijmans et al., 1999	+	+	+	?	+	+	+	+
Blanche et al., 2001	+	+	+	?	+	+	+	+
Panza et al., 2002	+	+	+	?	+	+	+	+
Choi et al., 2003	+	+	+	?	+	+	+	+
Panza et al., 2003	+	+	+	?	+	+	+	+
Wufuer et al., 2004	+	+	+	?	+	+	+	+
Seripa et al., 2006	+	+	+	?	+	+	+	+
Nacmias et al., 2007	+	+	+	?	+	+	+	+
Yang et al., 2009	+	+	+	?	+	+	+	+
Zhang et al., 2010	+	+	+	?	+	+	+	+
Fiuza-Luces et al., 2011	+	+	+	?	+	+	+	+
Lo Sasso et al., 2012	+	+	+	?	+	+	+	+
Arkhipova et al., 2014	+	+	+	?	-	+	+	+
Kolovou et al., 2014	+	+	?	?	+	+	+	+
Da Silva et al., 2018	+	+	+	?	+	+	+	+
Oscanoa et al., 2020	+	-	+	?	+	+	+	+

Domains:  
D1: Bias due to confounding.  
D2: Bias due to selection of participants.  
D3: Bias in classification of interventions.  
D4: Bias due to deviations from intended interventions.  
D5: Bias due to missing data.  
D6: Bias in measurement of outcomes.  
D7: Bias in selection of the reported result.

Judgement  
- Moderate  
+ Low  
? No information

**Figure 8A.** Traffic light plot showing the assessment of the risk of bias using ROBINS-1.

298



299

300

**Figure 8B.** Summary plot showing the assessment of the risk of bias using ROBINS-1.

301

302

303 **Discussion:**

304

305 Centenarians are the fastest-growing demographic group of the world's population, having  
306 roughly doubled every decade since 1950 (Wilcox et al., 2011). It has been nearly a decade  
307 since the most recent meta-analysis has been published in 2013 (Garatachea et al., 2013) and  
308 additional studies on centenarians and nonagenarians have been conducted that further  
309 elucidate the association between *ACE* genotype and longevity. In addition, the use of AI and  
310 machine-learning software has aided in the search and screening process to compile even more  
311 studies and process the associated data. Our meta-analysis suggests, with increased  
312 confidence, that there is a significant positive association of the DD genotype with exceptional  
313 longevity, across populations of different ethnicities. It has been reported that serum ACE levels  
314 correlate in the order of DD > ID > II in which DD is the highest (Rigat et al., 1990; Tired et al.,  
315 1992; Tomita et al., 1996). The higher levels of ACE were correlated with increased lifespans,  
316 especially more in centenarians than in long-lived controls.

317

318 The results present a couple of paradoxes in which the D-allele has been reported as a risk  
319 factor for hypertension (Li et al., 2011), CVD (Zintzaras et al., 2008), pneumonia (Nie et al.,  
320 2014) and COVID-19 (Yamamoto et al., 2020), all of which are major causes of death in older  
321 people. However, the DD genotype has been associated with a decreased risk of Alzheimer's  
322 disease, potentially due to ACE's ability to inhibit amyloid beta aggregation and degrade A beta-  
323 (1-40) (Hu et al., 2001; Kölsch et al., 2005; Lehmann et al., 2005). Although the protective effect  
324 of the D-allele against Alzheimer's disease does not fully explain the higher proportion of DD  
325 individuals in centenarian cohorts, the D-allele or DD genotype may impart a health risk while  
326 also providing a long-term longevity advantage. The middle-life crisis theory of aging (Murakami  
327 et al., 2011; Murakami, 2013; Machino et al., 2014; Le et al., 2021), in which midlife events are  
328 the catalyst for the transition from normal aging to a more advanced pathological state, can be  
329 used to explain ACE's dual functions as an angiotensin-converting enzyme and an amyloid-  
330 degrading enzyme (Le et al., 2021); low levels of ACE plasma activity, associated with the II  
331 genotype, may initially confer stress resistance before midlife, but will be insufficient to counter  
332 the abnormal accumulation of beta-amyloid when it begins and thus lead to higher mortality



333 rates earlier in the aging process due to AD, while DD individuals who had survived midlife  
334 comorbidities would now have lower mortality rates from AD. However, this does not fully  
335 explain the ACE paradox, as Alzheimer's disease is only one of many diseases that affect older  
336 people. As the full role of ACE in the human body has not been determined, the D-allele may  
337 have some neuroendocrine or immunomodulatory functions that have yet to be discovered  
338 (Costerousse et al., 1993) that may further explain ACE's role in longevity. It raises an  
339 unanswered key question how exceptional longevity is associated with positive risks of age-  
340 onset diseases that may increase the risk of mortality.

341

342 Another paradox is that inhibition of ACE by mutations or drugs can extend lifespans in model  
343 systems from nematodes, fruit flies, and mammals (reviewed in Le et al., 2021; Egan et al.,  
344 2022). The observation raises awareness that life-extension interventions in model systems  
345 may be different from exceptional longevity in humans. Thus, it raises another unanswered key  
346 question of whether or not exceptional longevity in humans shares common underlying  
347 mechanisms with life extension in model systems.

348

349 Our meta-analysis includes a comprehensive review of studies done on centenarians, from  
350 Schachter's initial study in 1994 up to the present, for a total of 2,054 centenarians. We did not  
351 limit the literature search to only studies written in English, thus our data represents all of the  
352 current ACE centenarian studies in the databases searched. The results corroborated the  
353 positive association between the DD genotype and exceptional longevity and the negative  
354 association between the II genotype and exceptional longevity that had been noted in previous  
355 meta-analyses. A novel finding was that the ID genotype, which had previously shown no  
356 significant associations with longevity, was found to have a significant negative association with  
357 longevity in the centenarian-only analysis.

358

359 It is implicated that the effect of ACE on health may differ among different age groups (Duc et  
360 al., 2021). Thus, we compared the centenarian-only data with the long-lived (85+ years old)  
361 data. We found that the distribution of ACE DD and II genotypes were consistent across both  
362 age groups, with strong associations in the DD genotype with exceptional longevity and with  
363 negative associations in the II genotype. Interestingly, the ID genotype had a significant  
364 negative association among centenarians but did not show a significant association among  
365 long-lived groups. The straightforward interpretations are as follows: (1) The DD genotype is  
366 associated with centenarians and is long-lived, while the D alleles follow the inheritance pattern  
367 of autosomal recessive; (2) The II genotype is negatively associated with longevity in both age  
368 groups; (3) The ID genotype shows a weakly negative association with centenarians, while the  
369 trend was not significant in long-lived control. Thus, more detailed studies with a series of ages  
370 will be needed.

371

372 The limitations of this study are as follows. Firstly, it can be summarized as a general limitation  
373 of the meta-analysis method. Each search engine list the papers which are indexed by its  
374 criteria, which may miss relevant studies. We included three search engines to reduce this risk  
375 of missing studies. Secondly, related to the first limitation is that the criteria to analyze the data  
376 rely on the criteria used in each study. For example, control groups of the past studies ranged

377 broadly and diverse (18-85 years old). There was a lack of detailed age groups to compare the  
378 effect of ACE. Thus, we were not able to have a series of ages to define age-dependent  
379 enrichment of the ACE D and I alleles. Thirdly, another limitation is that the vast majority of the  
380 centenarian studies on ACE used Caucasian populations. Selectively analyzing the studies of  
381 Caucasian populations gives the same results as the pooled data, indicating that there were no  
382 major differences in association across ethnicity within this present review. However, there  
383 were not enough Asian studies to sufficiently analyze the strength of association within Asian  
384 populations only. We also did not find any studies on ACE polymorphisms in Hispanic/Latino or  
385 Black centenarian cohorts in our literature search. For future meta-analyses, a greater diversity  
386 of such studies should be taken to better illuminate the role of ACE in aging populations across  
387 all different environmental or lifestyle risk factors.

388

389

### 390 **Conclusions:**

391

392 Our meta-analysis suggests a significant positive association between the ACE DD genotype  
393 with centenarians and long-lived groups. Although ACE polymorphisms are a risk factor for  
394 Alzheimer's disease and age-onset diseases that may contribute to mortality, the ACE DD  
395 genotype but not the ID genotype was in favor of exceptional longevity over the mortality  
396 expected in older people. The DD genotype is associated with a reduced risk of Alzheimer's  
397 disease and increased longevity. It is consistent with an ACE function as an amyloid  
398 degradation enzyme, which may be important in exceptional longevity in humans. Additionally,  
399 the DD genotype causes a high circulating ACE. In contrast, the DD genotype is also associated  
400 with an increased risk of various other diseases. They include hypertension (Li et al., 2011),  
401 ischemic stroke (Zhang et al., 2012), coronary artery disease (Zintzaras et al., 2008), left  
402 ventricular hypertrophy (Li et al., 2012) and pneumonia (Nie et al., 2014). Some of these  
403 diseases, including hypertension and cardiovascular conditions (stroke and coronary artery  
404 disease), are associated with the risks of COVID-19 mortality (Antos et al., 2021). The DD  
405 genotype is associated with higher COVID-19 mortality (Yamamoto et al., 2020). It may imply  
406 disease interactions mediated by the D allele. The underlying mechanisms of human longevity  
407 remain unclear, especially when considering the D-allele's role as a risk factor for many age-  
408 related comorbidities. Further studies on nonagenarians and centenarians of different  
409 backgrounds may provide better insight into the role of ACE as a longevity gene.

410

411

412 **Author Contributions:** L.L. was involved in data collection, organization of AI components, data  
413 analysis and writing of the manuscript. S.M. directed and guided all the research process.

414

415 **Funding:** This research received no external funding.

416

417 **Institutional Review Board Statement:** Not applicable.

418

419 **Informed Consent Statement:** Not applicable.

420

421 **Data Availability Statement:** The data supporting the reported results have been made  
422 available within the manuscript.

423

424 **Conflicts of Interest:** The authors declare no conflicts of interest.

425

426

## 427 References

- 428 1. Antos A, Kwong ML, Balmorez T, Villanueva A, Murakami S. (2021) Unusually High Risks  
429 of COVID-19 Mortality with Age-Related Comorbidities: An Adjusted Meta-Analysis  
430 Method to Improve the Risk Assessment of Mortality Using the Comorbid Mortality  
431 Data. *Infect Dis Rep.* 13(3):700-711. doi: 10.3390/idr13030065. PMID: 34449622;  
432 PMCID: PMC8395741.
- 433 2. Arkhipova, N. , Popova, E. and Grigorieva, L. (2014) The angiotension converting enzyme  
434 (ACE) gene I/D polymorphism in different ethnic groups of geriatric age living in the Far  
435 North. *Health*, 6, 426-431. doi: 10.4236/health.2014.65060.
- 436 3. Batrinos ML. (2008) The length of life and eugeria in classical Greece. *Hormones*  
437 (Athens). 7(1):82-3. doi: 10.14310/horm.2002.1111041. PMID: 18359748.
- 438 4. Beohar N, Damaraju S, Prather A, Yu QT, Raizner A, Kleiman NS, Roberts R, Marian AJ.  
439 (1995) Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery  
440 disease. *J Investig Med.* 43(3):275-80. PMID: 7614074.
- 441 5. Bladbjerg EM, Andersen-Ranberg K, de Maat MP, Kristensen SR, Jeune B, Gram J,  
442 Jespersen J. (1999) Longevity is independent of common variations in genes associated  
443 with cardiovascular risk. *Thromb Haemost.* 82(3):1100-5. PMID: 10494771.
- 444 6. Blanché H, Cabanne L, Sahbatou M, Thomas G. (2001) A study of French centenarians:  
445 are ACE and APOE associated with longevity? *C R Acad Sci III.* 324(2):129-35. doi:  
446 10.1016/s0764-4469(00)01274-9. PMID: 11280044.
- 447 7. Cheng, SH., Augustin, C., Bethel, A., Gill, D., Anzaroot, S., Brun, J., DeWilde, B., Minnich,  
448 R., Garside, R., Masuda, Y., Miller, DC., Wilkie, D., Wongbusarakum, S. and McKinnon,  
449 MC. (2018) Using machine learning to advance synthesis and use of conservation and  
450 environmental evidence. *Conservation Biology*, 32: 762-764. doi:10.1111/cobi.1311
- 451 8. Choi YH, Kim JH, Kim DK, Kim JW, Kim DK, Lee MS, Kim CH, Park SC. (2003) Distributions  
452 of ACE and APOE polymorphisms and their relations with dementia status in Korean  
453 centenarians. *J Gerontol A Biol Sci Med Sci.* 58(3):227-31. doi:  
454 10.1093/gerona/58.3.m227. PMID: 12634288.
- 455 9. Costa D, Scognamiglio M, Fiorito C, Benincasa G, Napoli C. Genetic background,  
456 epigenetic factors and dietary interventions which influence human longevity.  
457 *Biogerontology.* 2019 Oct;20(5):605-626. doi: 10.1007/s10522-019-09824-3. Epub 2019  
458 Jul 15. PMID: 31309340.
- 459 10. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. (1993) Angiotensin I-converting  
460 enzyme in human circulating mononuclear cells: genetic polymorphism of expression in  
461 T-lymphocytes. *Biochem J.* 290 (Pt1)(Pt1):33-40. doi: 10.1042/bj2900033. PMID:  
462 8382480; PMCID: PMC1132379.
- 463 11. Faure-Delanef L, Baudin B, Bénéteau-Burnat B, Beaudoin JC, Giboudeau J, Cohen D.  
464 (1998) Plasma concentration, kinetic constants, and gene polymorphism of angiotensin  
465 I-converting enzyme in centenarians. *Clin Chem.* 44(10):2083-7. PMID: 9761238.
- 466 12. Fiuza-Luces C, Ruiz JR, Rodríguez-Romo G, Santiago C, Gómez-Gallego F, Cano-Nieto A,  
467 Garatachea N, Rodríguez-Moreno I, Morán M, Lucia A. (2011) Is the ACE I/D  
468 polymorphism associated with extreme longevity? A study on a Spanish cohort. *J Renin*  
469 *Angiotensin Aldosterone Syst.* 12(3):202-7. doi: 10.1177/1470320310391505. Epub 2011  
470 Feb 17. PMID: 21330423.

- 471 13. Garatachea N, Marín PJ, Lucia A. (2013) The ACE DD genotype and D-allele are  
472 associated with exceptional longevity: a meta-analysis. *Ageing Res Rev.* 12(4):1079-87.  
473 doi: 10.1016/j.arr.2013.04.001. Epub 2013 Apr 23. PMID: 23623925.
- 474 14. Gareri P, Lacava R, Rossi MG, Iorio C, Galasso MA, Pansini L, Curti A, Mercurio M, Olivo  
475 D, Mattace R. (1996) Hypertension in a group of centenarians. *Arch Gerontol Geriatr.* 22  
476 Suppl 1:373-6. doi: 10.1016/0167-4943(96)86964-0. PMID: 18653059.
- 477 15. Heijmans BT, Westendorp RG, Knook DL, Klufft C, Slagboom PE. (1999) Angiotensin I-  
478 converting enzyme and plasminogen activator inhibitor-1 gene variants: risk of mortality  
479 and fatal cardiovascular disease in an elderly population-based cohort. *J Am Coll Cardiol.*  
480 34(4):1176-83. doi: 10.1016/s0735-1097(99)00337-x. PMID: 10520809.
- 481 16. Hu J, Igarashi A, Kamata M, Nakagawa H. (2001) Angiotensin-converting enzyme  
482 degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation,  
483 deposition, fibril formation; and inhibits cytotoxicity. *J Biol Chem.* 276(51):47863-8. doi:  
484 10.1074/jbc.M104068200. Epub 2001 Oct 16. PMID: 11604391.
- 485 17. Jopp DS, Boerner K, Rott C. (2016) Health and Disease at Age 100. *Dtsch Arztebl Int.*  
486 113(12):203-10. doi: 10.3238/arztebl.2016.0203. Erratum in: *Dtsch Arztebl Int.* 2016  
487 113(22-23):395. PMID: 27118718; PMCID: PMC5400033.
- 488 18. Kolovou G, Kolovou V, Vasiliadis I, Giannakopoulou V, Mihas C, Bilianou H, Kollia A,  
489 Papadopoulou E, Marvaki A, Goumas G, Kalogeropoulos P, Limperi S, Katsiki N,  
490 Mavrogeni S. (2013) The frequency of 4 common gene polymorphisms in  
491 nonagenarians, centenarians, and average life span individuals. *Angiology.* 65(3):210-5.  
492 doi: 10.1177/0003319712475075. PMID: 23389097.
- 493 19. Kölsch H, Jessen F, Freymann N, Kreis M, Hentschel F, Maier W, Heun R. (2005) ACE I/D  
494 polymorphism is a risk factor of Alzheimer's disease but not of vascular dementia.  
495 *Neurosci Lett.* 377(1):37-9. doi: 10.1016/j.neulet.2004.11.062. Epub 2004 Dec 10. PMID:  
496 15722183.
- 497 20. Le D, Brown L, Malik K, Murakami S. (2021) Two Opposing Functions of Angiotensin-  
498 Converting Enzyme (ACE) That Links Hypertension, Dementia, and Aging. *Int J Mol Sci.*  
499 22(24):13178. doi: 10.3390/ijms222413178. PMID: 34947975; PMCID: PMC8707689.
- 500 21. Le D, Crouch N, Villanueva A, Ta P, Dmitriyev R, Tsunzi M and Murakami S. (2020)  
501 Evidence-Based Genetics and Identification of Key Human Alzheimer's Disease Alleles  
502 with Co-morbidities. *J Neurol Exp Neurosci* 6(1): 20-24.
- 503 22. Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Slegers K, Prince JA, van Duijn  
504 CM, Kehoe PG. (2005) Large meta-analysis establishes the ACE insertion-deletion  
505 polymorphism as a marker of Alzheimer's disease. *Am J Epidemiol.* 162(4):305-17. doi:  
506 10.1093/aje/kwi202. Epub 2005 Jul 20. PMID: 16033878.
- 507 23. Li X, Li Y, Jia N, Guo S, Chu S, Niu W. (2012) Angiotensin-converting enzyme gene  
508 deletion allele increases the risk of left ventricular hypertrophy: evidence from a meta-  
509 analysis. *Mol Biol Rep.* 39(12):10063-75. doi: 10.1007/s11033-012-1875-6. Epub 2012 Jul  
510 7. PMID: 22773337.
- 511 24. Li Y. (2012) Angiotensin-converting enzyme gene insertion/deletion polymorphism and  
512 essential hypertension in the Chinese population: a meta-analysis including 21,058  
513 participants. *Intern Med J.* 2012 Apr;42(4):439-44. doi: 10.1111/j.1445-  
514 5994.2011.02584.x. PMID: 21883781.

- 515 25. Lo Sasso, B., Bellia, C., Tomaiuolo, R., Zarrilli, F., Scorza, M., Caruso, A., et al. (2013).  
516 Polimorfismo I/D del gene per l'enzima di conversione dell'angiotensina (ACE): gene  
517 della longevità o fattore di rischio nella patologia ipertensiva?. *Biochimica Clinica*,  
518 37(37), 461-464.
- 519 26. Machino K, Link CD, Wang S, Murakami H, Murakami S. A semi-automated motion-  
520 tracking analysis of locomotion speed in the *C. elegans* transgenics overexpressing beta-  
521 amyloid in neurons. *Front Genet*. 2014 Jul 4;5:202. doi: 10.3389/fgene.2014.00202.  
522 PMID: 25071831; PMCID: PMC4082091.
- 523 27. McGuinness LA, Higgins JPT. (2021) Risk-of-bias VISualization (robvis): An R package and  
524 Shiny web app for visualizing risk-of-bias assessments. *Res Synth Methods*. 12(1):55-61.  
525 doi: 10.1002/jrsm.1411. PMID: 32336025.
- 526 28. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. (2009) Preferred reporting  
527 items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*.  
528 6(7):e1000097. doi: 10.1371/journal.pmed.1000097. PMID: 19621072; PMCID:  
529 PMC2707599.
- 530 29. Montagu JD. (1994) Length of life in the ancient world: a controlled study. *J R Soc Med*.  
531 87(1):25-6. PMID: 8308825; PMCID: PMC1294277.
- 532 30. Murakami, S. (2013) Age-dependent modulation of learning and memory in *C. elegans*.  
533 In Menzel R and Benjamin P.R. (Eds.) *Invertebrate Learning and Memory; Handbook of*  
534 *Behavioral Neuroscience*. Elsevier/Academic Press. Ch.12, Pages 140-150.
- 535 31. Murakami, S., Cabana, K., Anderson, D. (2011) Current advances in the study of  
536 oxidative stress and age-related memory impairment in *C. elegans*. In Farooqui, T.  
537 Farooqui, A. (Ed.) *Molecular aspects of oxidative stress on cell signaling in vertebrates*  
538 *and invertebrates*, John Wiley & Sons, Hoboken, NJ. Ch 25, Pages 347-360.
- 539 32. Murakami S, Lacayo P. (2022) Biological and disease hallmarks of Alzheimer's disease  
540 defined by Alzheimer's disease genes. *Front Aging Neurosci*. 14:996030. doi:  
541 10.3389/fnagi.2022.996030. PMID: 36437990; PMCID: PMC9682170.
- 542 33. Nacmias B, Bagnoli S, Tedde A, Cellini E, Bessi V, Guarnieri B, Ortensi L, Piacentini S,  
543 Bracco L, Sorbi S. (2007) Angiotensin converting enzyme insertion/deletion  
544 polymorphism in sporadic and familial Alzheimer's disease and longevity. *Arch Gerontol*  
545 *Geriatr*. 45(2):201-6. doi: 10.1016/j.archger.2006.10.011. Epub 2006 Dec 19. PMID:  
546 17182125.
- 547 34. Nie W, Zang Y, Chen J, Liu T, Xiao L, Xiu Q. (2014) Angiotensin-converting enzyme I/D  
548 polymorphism is associated with pneumonia risk: a meta-analysis. *J Renin Angiotensin*  
549 *Aldosterone Syst*. 15(4):585-92. doi: 10.1177/1470320313507622. Epub 2014 Feb 4.  
550 PMID: 24496515.
- 551 35. Oscanoa TJ, Cieza EC, Lizaraso-Soto FA, Guevara ML, Fujita RM, Romero-Ortuño R.  
552 (2020) Angiotensin-Converting Enzyme (ACE) genetic variation and longevity in Peruvian  
553 older people: a cross-sectional study. *Ann Hum Biol*. 47(3):309-312. doi:  
554 10.1080/03014460.2020.1748227. PMID: 32281429.
- 555 36. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L,  
556 Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu  
557 MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J,  
558 Tricco AC, Welch VA, Whiting P, Moher D. (2021) The PRISMA 2020 statement: an



- 559 updated guideline for reporting systematic reviews. *BMJ*. 372:n71. doi:  
560 10.1136/bmj.n71. PMID: 33782057; PMCID: PMC8005924.
- 561 37. Panza, F., Solfrizzi, V., D'Introno, A., Capurso, C., Basile, A.M., Colacicco, A.M., Sabba, M.,  
562 Noya, R., Capurso, A. (2002) Apolipoprotein and angiotensin converting enzyme genes:  
563 regional differences and extreme longevity in Europe. *Archives of Gerontology and*  
564 *Geriatrics Supplement* 8, 247–251
- 565 38. Panza F, Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Kehoe PG, Capurso A. (2003)  
566 Angiotensin I converting enzyme (ACE) gene polymorphism in centenarians: different  
567 allele frequencies between the North and South of Europe. *Exp Gerontol*. 38(9):1015-20.  
568 doi: 10.1016/s0531-5565(03)00154-2. PMID: 12954489.
- 569 39. Pereira da Silva A, Matos A, Aguiar L, Ramos-Marques N, Ribeiro R, Gil Â, Gorjão-Clara J,  
570 Bicho M. (2019) Hypertension and longevity: role of genetic polymorphisms in renin-  
571 angiotensin-aldosterone system and endothelial nitric oxide synthase. *Mol Cell*  
572 *Biochem*. 455(1-2):61-71. doi: 10.1007/s11010-018-3470-1. PMID: 30460536.
- 573 40. Revelas M, Thalamuthu A, Oldmeadow C, Evans TJ, Armstrong NJ, Kwok JB, Brodaty H,  
574 Schofield PR, Scott RJ, Sachdev PS, Attia JR, Mather KA. (2018) Review and meta-analysis  
575 of genetic polymorphisms associated with exceptional human longevity. *Mech Ageing*  
576 *Dev*. 175:24-34. doi: 10.1016/j.mad.2018.06.002. PMID: 29890178.
- 577 41. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. (1990) An  
578 insertion/deletion polymorphism in the angiotensin I-converting enzyme gene  
579 accounting for half the variance of serum enzyme levels. *J Clin Invest*. 86(4):1343-6. doi:  
580 10.1172/JCI114844. PMID: 1976655; PMCID: PMC296868.
- 581 42. Roser M, Ortiz-Ospina E, Ritchie H (2013) Life Expectancy. *OurWorldInData.org*.  
582 Retrieved on Nov 29, 2022 from: <https://ourworldindata.org/life-expectancy>
- 583 43. Schächter F, Faure-Delanef L, Guénot F, Rouger H, Froguel P, Lesueur-Ginot L, Cohen D.  
584 (1994) Genetic associations with human longevity at the APOE and ACE loci. *Nat Genet*.  
585 6(1):29-32. doi: 10.1038/ng0194-29. PMID: 8136829.
- 586 44. Seripa D, Franceschi M, Matera MG, Panza F, Kehoe PG, Gravina C, Orsitto G, Solfrizzi V,  
587 Di Minno G, Dallapiccola B, Pilotto A. (2006) Sex differences in the association of  
588 apolipoprotein E and angiotensin-converting enzyme gene polymorphisms with healthy  
589 aging and longevity: a population-based study from Southern Italy. *J Gerontol A Biol Sci*  
590 *Med Sci*. 61(9):918-23. doi: 10.1093/gerona/61.9.918. PMID: 16960022.
- 591 45. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D,  
592 Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ,  
593 Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein  
594 HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L,  
595 Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP. (2016) ROBINS-  
596 I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*.  
597 355:i4919. doi: 10.1136/bmj.i4919. PMID: 27733354; PMCID: PMC5062054.
- 598 46. Tomita H, Ina Y, Sugiura Y, Sato S, Kawaguchi H, Morishita M, Yamamoto M, Ueda R.  
599 (1997) Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis.  
600 *Am J Respir Crit Care Med*. 156(1):255-9. doi: 10.1164/ajrccm.156.1.9612011. PMID:  
601 9230757.

- 602 47. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F. Evidence, from  
603 combined segregation and linkage analysis, that a variant of the angiotensin I-converting  
604 enzyme (ACE) gene controls plasma ACE levels. *Am J Hum Genet.* 1992 Jul;51(1):197-  
605 205. PMID: 1319114; PMCID: PMC1682892.
- 606 48. Vahdati Nia B, Kang C, Tran MG, Lee D, Murakami S. (2017) Meta Analysis of Human  
607 AlzGene Database: Benefits and Limitations of Using *C. elegans* for the Study of  
608 Alzheimer's Disease and Co-morbid Conditions. *Front Genet.* 2017 8:55. doi:  
609 10.3389/fgene.2017.00055. PMID: 28553317; PMCID: PMC5427079.
- 610 49. Weinert BT, Timiras PS. Theories of aging. *J Appl Physiol.* (2003) 95(4):1706-16. doi:  
611 10.1152/jappphysiol.00288.2003. PMID: 12970376.
- 612 50. Wufuer M, Fang MW, Cheng ZH, Qiu CC. (2004) [Polymorphism of angiotensin  
613 converting enzyme gene and natural longevity in the Xinjiang Uygur people: an  
614 association study]. *Zhonghua Yi Xue Za Zhi.* 84(19):1603-6. Chinese. PMID: 15569453.
- 615 51. Yang JK, Gong YY, Xie L, Lian SG, Yang J, Xu LY, Gao SJ, Zhang YP. (2009) Lack of genetic  
616 association between the angiotensin-converting enzyme gene insertion/deletion  
617 polymorphism and longevity in a Han Chinese population. *J Renin Angiotensin  
618 Aldosterone Syst.* 10(2):115-8. doi: 10.1177/1470320309104873. PMID: 19502260.
- 619 52. Zhang WF, Ling JH, Wang AJ. (2010) [Relationship between shen-deficiency syndrome  
620 and polymorphism of angiotensin converting enzyme gene in longevous elders in Bama  
621 area of Guangxi municipality]. *Zhongguo Zhong Xi Yi Jie He Za Zhi.* 30(3):259-63. Chinese.  
622 PMID: 20535922.
- 623 53. Zintzaras E, Raman G, Kitsios G, Lau J. (2008) Angiotensin-converting enzyme  
624 insertion/deletion gene polymorphic variant as a marker of coronary artery disease: a  
625 meta-analysis. *Arch Intern Med.* 168(10):1077-89. doi: 10.1001/archinte.168.10.1077.  
626 PMID: 18504336.